-
EP4059504
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4059504
| EP4059504 - DRUG SUBSTANCE OF LEMBOREXANT AND MEDICINAL COMPOSITION COMPRISING SAME [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 23.10.2025 Database last updated on 14.03.2026 | |
| Former | Request for examination was made Status updated on 19.08.2022 | ||
| Former | The international publication has been made Status updated on 23.07.2021 | Most recent event Tooltip | 30.01.2026 | New entry: Reply to examination report | 30.01.2026 | New entry: Renewal fee paid | Applicant(s) | For all designated states Eisai R&D Management Co., Ltd. 4-6-10 Koishikawa Bunkyo-ku Tokyo 112-8088 / JP | [N/P] |
| Former [2022/38] | For all designated states Eisai R&D Management Co., Ltd. 4-6-10 Koishikawa Bunkyo-ku Tokyo 112-8088 / JP | Inventor(s) | 01 /
ABE, Taichi C/O Eisai Co., Ltd. Kashima Plant, 22, Sunayama Kamisu-shi, Ibaraki 314-0255 / JP | 02 /
AYATA, Yusuke C/O Eisai Co., Ltd. Kashima Plant, 22, Sunayama Kamisu-shi, Ibaraki 314-0255 / JP | 03 /
SUZUKI, Nobuya C/O Eisai Co., Ltd. Kawashima Industrial Complex 1, Kawashimatakehaya-machi Kakamigahara-shi, Gifu 501-6024 / JP | 04 /
AKIMOTO, Yurie C/O Eisai Co., Ltd. Kawashima Industrial Complex 1, Kawashimatakehaya-machi Kakamigahara-shi, Gifu 501-6024 / JP | 05 /
SHIKATA, Futoshi C/O Eisai Co., Ltd. Kawashima Industrial Complex 1, Kawashimatakehaya-machi Kakamigahara-shi, Gifu 501-6024 / JP | 06 /
ZAIMA, Yasuhiro C/O Eisai Co., Ltd. Kawashima Industrial Complex 1, Kawashimatakehaya-machi Kakamigahara-shi, Gifu 501-6024 / JP | 07 /
YOSHIDA, Nobuo C/O Eisai Co., Ltd., 4-6-10 Koishikawa, Bunkyo-ku Tokyo 112-8088 / JP | [2022/38] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [2022/38] | Application number, filing date | 21741344.2 | 14.01.2021 | [2022/38] | WO2021JP01027 | Priority number, date | JP20200005214 | 16.01.2020 Original published format: JP 2020005214 | [2022/38] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021145373 | Date: | 22.07.2021 | Language: | JA | [2021/29] | Type: | A1 Application with search report | No.: | EP4059504 | Date: | 21.09.2022 | Language: | EN | [2022/38] | Search report(s) | International search report - published on: | JP | 22.07.2021 | (Supplementary) European search report - dispatched on: | EP | 27.11.2023 | Classification | IPC: | A61K9/16, A61K9/20, A61K31/506, A61P25/20, A61P43/00 | [2023/52] | CPC: |
A61P25/20 (EP,IL,KR);
A61K31/506 (EP,IL,KR,US);
A61K9/14 (KR);
A61K9/1652 (EP);
A61K9/1688 (US);
A61K9/2013 (US);
|
| Former IPC [2022/38] | A61K31/506, A61P25/20, A61P43/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/38] | Title | German: | ARZNEISTOFF AUS LEMBOREXANT UND DIESE ENTHALTENDE MEDIZINISCHE ZUSAMMENSETZUNG | [2022/38] | English: | DRUG SUBSTANCE OF LEMBOREXANT AND MEDICINAL COMPOSITION COMPRISING SAME | [2022/38] | French: | SUBSTANCE MÉDICAMENTEUSE DE LEMBOREXANT ET COMPOSITION MÉDICINALE COMPRENANT CELLE-CI | [2022/38] | Entry into regional phase | 13.06.2022 | Translation filed | 13.06.2022 | National basic fee paid | 13.06.2022 | Search fee paid | 13.06.2022 | Designation fee(s) paid | 13.06.2022 | Examination fee paid | Examination procedure | 13.06.2022 | Examination requested [2022/38] | 05.06.2024 | Amendment by applicant (claims and/or description) | 05.06.2024 | Date on which the examining division has become responsible | 22.10.2025 | Despatch of a communication from the examining division (Time limit: M04) | 27.01.2026 | Reply to a communication from the examining division | Fees paid | Renewal fee | 25.01.2023 | Renewal fee patent year 03 | 25.01.2024 | Renewal fee patent year 04 | 28.01.2025 | Renewal fee patent year 05 | 29.01.2026 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I] WO2019024845 (CRYSTAL PHARMACEUTICAL SUZHOU CO LTD et al.) [I] 1-15 * page 1, lines 22-25 * * examples 13, 14 * * figure 15 * | [DI] WO2016063995 (EISAI R&D MAN CO LTD et al.) [DI] 1-15 * pages 1-2, paragraph 0003 * * page 26, paragraph 0155 - page 28, paragraph 0165 * * example 5 * * figures 1, 2 * | International search | [Y] JP2019518732 (エーザイ・アール・アンド・ディー・マネジメント株式会社) | [Y] WO2012039371 (EISAI R&D MAN CO LTD et al.) | [Y] JP2016044170 (NIPPON CHEMIPHAR CO et al.) | [Y] JP2002531403 | [Y] "Basic course on drug development", 28 June 1975, CHIJIN SHOKAN CO., article TSUDA, KYOSUKE: "Formulation design method (1) Biopharmacy", pages: 528, XP009537105 | by applicant | WO2012039371 | WO2013123240 | WO2016063995 | SAKURAI T. ET AL., CELL, vol. 92, 1998, pages 573 - 585 | CHEMELLI R. M. ET AL., CELL, vol. 98, 1999, pages 437 - 451 | S. L. BORGLAND ET AL., NEURON, vol. 49, 2006, pages 598 - 601 | C. J. WINROW ET AL., NEUROPHARMACOLOGY, vol. 58, 2010, pages 185 - 194 | J. R. SHOBLOCK ET AL., PSYCHOPHARMACOLOGY, vol. 215, 2011, pages 191 - 203 | T. IDA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 270, 2000, pages 318 - 323 | "Japanese Pharmacopoeia" |